Rinucumab

DB16313InvestigationalProtein Based Therapies

Rinucumab is under investigation in clinical trial NCT02418754 (Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-related Macular Degeneration (AMD)).

Mechanism: Pharmacologically active on Platelet-derived growth factor receptor beta
Curator reviewed
Also known as: Immunoglobulin g4, anti-(human platelet-derived growth factor receptor~) (human monoclonal regn2176 heavy chain), disulfide with human monoclonal regn2176 k-chain, dimer
Code names: REGN-2176

Resolves to

Compound

UNII10E3O6YI4WCAS1569263-06-4

Targets

P09619PDGFRB

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rinucumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account